Sugi Predict

Sugi Predict / Targets / PKD1

PKD1

Polycystin-1 · P98161 · PKD1 on Sugi Atlas →

2,467 patent compounds predicted against PKD1, 2,151 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL16547245 SCHEMBL16547245 0.71 2/20
SCHEMBL16547176 SCHEMBL16547176 0.66 2/20
SCHEMBL16547153 SCHEMBL16547153 0.63 2/20
SCHEMBL16505956 SCHEMBL16505956 0.54 2/20
SCHEMBL16516753 SCHEMBL16516753 0.53 2/20
SCHEMBL16532311 SCHEMBL16532311 0.52 2/20
SCHEMBL16505717 SCHEMBL16505717 0.49 2/20
SCHEMBL16506173 SCHEMBL16506173 0.49 2/20
SCHEMBL17233511 SCHEMBL17233511 0.47 2/20
SCHEMBL17243638 SCHEMBL17243638 0.47 2/20
SCHEMBL17243626 SCHEMBL17243626 0.46 2/20
SCHEMBL16517110 SCHEMBL16517110 0.46 2/20
SCHEMBL16532427 SCHEMBL16532427 0.44 2/20
SCHEMBL17233514 SCHEMBL17233514 0.43 2/20
SCHEMBL17243928 SCHEMBL17243928 0.43 2/20
SCHEMBL16532351 SCHEMBL16532351 0.43 2/20
SCHEMBL17243925 SCHEMBL17243925 0.41 2/20
SCHEMBL16532403 SCHEMBL16532403 0.41 2/20
SCHEMBL17233522 SCHEMBL17233522 0.40 2/20
SCHEMBL16532569 SCHEMBL16532569 0.40 2/20

Clinical trials — most relevant to PKD1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) PHASE4ACTIVE_NOT_RECRUITING
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease PHASE2/PHASE3COMPLETED
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) PHASE3COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Bempedoic Acid Therapy for Polycystic Kidney Disease PHASE2NOT_YET_RECRUITING
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease PHASE2COMPLETED
Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2) PHASE2COMPLETED
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) PHASE2COMPLETED
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease PHASE2COMPLETED
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 PHASE1RECRUITING
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease PHASE1RECRUITING
The Vienna RAP Pilot Study nanCOMPLETED
Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository nanENROLLING_BY_INVITATION
A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province nanCOMPLETED
Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease nanACTIVE_NOT_RECRUITING
Imaging Assessments of ARPKD Kidney Disease Progression nanRECRUITING
Evaluation of Nephrectomy Specimen for Intracranial Aneurysm Development in ADPKD nanCOMPLETED
Evaluation of Iliac and Renal Artery for Mechanism of Intracranial Aneurysm in ADPKD nanUNKNOWN
High Water Intake in Polycystic Kidney Disease nanCOMPLETED
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease nanACTIVE_NOT_RECRUITING
Early PKD Observational Cohort Study nanRECRUITING
Outcome of ADPKD With Octreotide LAR nanACTIVE_NOT_RECRUITING
Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease nanCOMPLETED
Role of ROS and cAMP-PKA Biomarkers in ADPKD nanACTIVE_NOT_RECRUITING
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping nanCOMPLETED
Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease nanNOT_YET_RECRUITING
A Prospective Observational Study of Foam Sclerotherapy . nanRECRUITING
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease nanCOMPLETED
Pyruvate Kinase Deficiency Natural History Study nanCOMPLETED
Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PKD1 binder may also engage these)

ProteinNameSimilarity
O08852 — 0.995 O08852 →
O88671 — 0.991 O88671 →
Q28680 — 0.990 Q28680 →
Q9CZT5 — 0.990 Q9CZT5 →
D3ZT86 — 0.989 D3ZT86 →
Q7Z4F1 — 0.989 Q7Z4F1 →
Q86VR7 — 0.988 Q86VR7 →
Q01634 — 0.988 Q01634 →
Q7TQH7 — 0.987 Q7TQH7 →
Q8NI99 — 0.987 Q8NI99 →
Q5IJ48 — 0.987 Q5IJ48 →
Q9Z0J7 — 0.987 Q9Z0J7 →
Q9NYJ7 — 0.987 Q9NYJ7 →
Q8BLY7 — 0.986 Q8BLY7 →
O95502 — 0.986 O95502 →
Q86VZ4 — 0.986 Q86VZ4 →
O75064 — 0.986 O75064 →
P20863 — 0.986 P20863 →
O35764 — 0.985 O35764 →
G3MZC5 — 0.985 G3MZC5 →
Q6EMK4 — 0.985 Q6EMK4 →
CD14 Monocyte differentiation antigen CD14 0.984 landscape →
Q9BDW8 — 0.984 Q9BDW8 →
Q96FS4 — 0.983 Q96FS4 →
Q7TN88 — 0.983 Q7TN88 →
D3YZF7 — 0.983 D3YZF7 →
Q9BY79 — 0.983 Q9BY79 →
O95428 — 0.983 O95428 →
Q8WWN8 — 0.982 Q8WWN8 →
A6NE52 — 0.982 A6NE52 →